Cargando…

The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.

Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) is a long non-coding RNA, which has found to unregulated in various kinds of cancer. This meta-analysis was conducted to demonstrate the association between ZEB1-AS1 expression levels and clinical outcome or prognosis of cancer patients.10...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Ying, Fang, Jian, Zhu, Linqi, Jiang, Hui, Liu, Yun, Miao, Renjie, Shao, Chen, Shao, Shihe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036884/
https://www.ncbi.nlm.nih.gov/pubmed/30026848
http://dx.doi.org/10.7150/jca.25264
_version_ 1783338244725800960
author Ni, Ying
Fang, Jian
Zhu, Linqi
Jiang, Hui
Liu, Yun
Miao, Renjie
Shao, Chen
Shao, Shihe
author_facet Ni, Ying
Fang, Jian
Zhu, Linqi
Jiang, Hui
Liu, Yun
Miao, Renjie
Shao, Chen
Shao, Shihe
author_sort Ni, Ying
collection PubMed
description Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) is a long non-coding RNA, which has found to unregulated in various kinds of cancer. This meta-analysis was conducted to demonstrate the association between ZEB1-AS1 expression levels and clinical outcome or prognosis of cancer patients.10 studies with 783 cancer patients were included in this meta-analysis by retrieving 5 databases (PubMed Central, EMBASE, Cochrane Library, Wiley Online Library and Medline).The result showed that overexpression of ZEB1-AS1 is significantly correlated with poor OS (Hazard ratio, HR=2.45, 95% confidence interval, CI: 1.89-3.16). ZEB1-AS1 expression levels were also associated with clinicopathological parameters including lymph node metastasis (Yes vs. No; OR=4.00, 95%CI: 2.23-7.17, P<0.00001), histologic differentiation (Moderate + poor vs. Well; OR=2.72, 95% CI: 1.69-4.37, p<0.0001), tumor metastasis and invasion (Yes vs. No; OR =2.52, 95%CI: 1.12-5.68, P=0.03) and TNM stage (III+IV vs. I+II; OR=2.76, 95 %CI 1.46-5.21, P=0.002). However, ZEB1-AS1 expression was not significantly associated with patients' gender (Male vs. Female; OR=1.20, 95% CI: 0.87-1.66; P=0.27).This meta-analysis indicated the potential value of ZEB1-AS1 as a biomarker for predicting a poor prognosis in patients with cancer.
format Online
Article
Text
id pubmed-6036884
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-60368842018-07-19 The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer. Ni, Ying Fang, Jian Zhu, Linqi Jiang, Hui Liu, Yun Miao, Renjie Shao, Chen Shao, Shihe J Cancer Research Paper Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) is a long non-coding RNA, which has found to unregulated in various kinds of cancer. This meta-analysis was conducted to demonstrate the association between ZEB1-AS1 expression levels and clinical outcome or prognosis of cancer patients.10 studies with 783 cancer patients were included in this meta-analysis by retrieving 5 databases (PubMed Central, EMBASE, Cochrane Library, Wiley Online Library and Medline).The result showed that overexpression of ZEB1-AS1 is significantly correlated with poor OS (Hazard ratio, HR=2.45, 95% confidence interval, CI: 1.89-3.16). ZEB1-AS1 expression levels were also associated with clinicopathological parameters including lymph node metastasis (Yes vs. No; OR=4.00, 95%CI: 2.23-7.17, P<0.00001), histologic differentiation (Moderate + poor vs. Well; OR=2.72, 95% CI: 1.69-4.37, p<0.0001), tumor metastasis and invasion (Yes vs. No; OR =2.52, 95%CI: 1.12-5.68, P=0.03) and TNM stage (III+IV vs. I+II; OR=2.76, 95 %CI 1.46-5.21, P=0.002). However, ZEB1-AS1 expression was not significantly associated with patients' gender (Male vs. Female; OR=1.20, 95% CI: 0.87-1.66; P=0.27).This meta-analysis indicated the potential value of ZEB1-AS1 as a biomarker for predicting a poor prognosis in patients with cancer. Ivyspring International Publisher 2018-06-15 /pmc/articles/PMC6036884/ /pubmed/30026848 http://dx.doi.org/10.7150/jca.25264 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Ni, Ying
Fang, Jian
Zhu, Linqi
Jiang, Hui
Liu, Yun
Miao, Renjie
Shao, Chen
Shao, Shihe
The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.
title The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.
title_full The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.
title_fullStr The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.
title_full_unstemmed The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.
title_short The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.
title_sort significant prognostic value of zeb1-as1 up-regulation in patients with cancer.
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036884/
https://www.ncbi.nlm.nih.gov/pubmed/30026848
http://dx.doi.org/10.7150/jca.25264
work_keys_str_mv AT niying thesignificantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT fangjian thesignificantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT zhulinqi thesignificantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT jianghui thesignificantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT liuyun thesignificantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT miaorenjie thesignificantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT shaochen thesignificantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT shaoshihe thesignificantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT niying significantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT fangjian significantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT zhulinqi significantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT jianghui significantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT liuyun significantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT miaorenjie significantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT shaochen significantprognosticvalueofzeb1as1upregulationinpatientswithcancer
AT shaoshihe significantprognosticvalueofzeb1as1upregulationinpatientswithcancer